one
year
occurr
first
case
infect
middl
east
respiratori
syndrom
coronaviru
merscov
clear
consensu
best
treatment
propos
world
health
organ
well
sever
nation
agenc
still
work
differ
clinic
approach
implement
relev
treatment
merscov
infect
compar
innat
adapt
immun
respons
two
patient
infect
merscov
understand
underli
mechan
involv
respons
propos
potenti
therapeut
approach
bronchoalveolar
lavag
bal
first
week
sera
first
month
two
patient
use
studi
quantit
polymeras
chain
reaction
qrtpcr
perform
extract
rna
bal
cell
merscov
infect
patient
control
patient
bal
supernat
sera
use
assess
cytokin
chemokin
secret
enzymelink
immunosorb
assay
first
patient
die
rapidli
week
intens
care
unit
second
patient
still
recov
infect
patient
poor
outcom
patient
compar
patient
promot
interferon
ifn
particularli
ifna
respons
doubl
strand
rna
dsrna
merscov
absenc
ifna
known
promot
antigen
present
respons
virus
impair
develop
robust
antivir
adapt
immun
respons
respons
mediat
ifnc
decreas
viral
clearanc
level
mediat
decreas
patient
final
confirm
previou
vitro
find
merscov
drive
product
human
host
recognit
viral
dsrna
determin
outcom
earli
stage
merscov
infect
highlight
critic
role
ifna
initi
stage
orchestr
robust
immun
respons
bring
substanti
argument
indic
earli
ifna
treatment
merscov
infect
coronavirus
larg
envelop
singlestrand
rna
virus
associ
wide
rang
clinic
present
anim
human
septemb
novel
human
coronaviru
name
middl
east
respiratori
syndrom
coronaviru
merscov
belong
lineag
c
genu
betacoronaviru
identifi
two
patient
sever
acut
respiratori
diseas
saudi
arabia
sever
countri
franc
germani
jordan
qatar
saudi
arabia
tunisia
unitedkingdom
report
new
case
recent
assiri
et
al
publish
extens
descript
case
saoudi
arabia
coronavirus
like
success
virus
evolv
strategi
evad
innat
immun
respons
interferon
ifn
express
crucial
compon
initi
respons
coronavirus
develop
strategi
prevent
ifn
induct
doublestrand
rna
dsrna
recogn
innat
immun
system
activ
cytosol
membran
pattern
recognit
receptor
prr
recognit
prr
trigger
activ
interferon
regulatori
factor
lead
induct
interferon
ifna
ifnb
ifn
activ
immun
antivir
effector
natur
killer
nk
cell
cell
macrophag
allow
viral
clearanc
consist
studi
demonstr
sever
acut
respiratori
syndrom
sar
cov
protein
contribut
dampen
ifn
signal
evad
innat
immun
viral
clearanc
vitro
studi
report
benefici
effect
interferonalpha
ifna
treatment
merscov
replic
cellular
model
studi
author
show
merscov
time
sensit
ifna
treatment
sarscov
howev
date
clear
therapeut
protocol
besid
support
treatment
merscov
infect
report
analysi
immun
respons
two
concomit
case
patient
infect
merscov
admit
lill
univers
teach
hospit
april
june
clinic
present
previous
report
outcom
two
patient
larg
differ
inde
first
patient
die
one
month
intens
care
unit
second
patient
still
recov
infect
compar
earli
immun
respons
two
patient
describ
put
underli
mechan
merscov
infect
propos
potenti
therapeut
target
bronchoalveolar
lavag
bal
sampl
obtain
sampl
bal
perform
first
week
onset
symptom
two
infect
patient
patient
n
duplic
patient
n
duplic
control
sampl
n
obtain
patient
pulmonolog
depart
requir
bal
reason
respiratori
tract
infect
addit
control
sampl
bacteri
respiratori
tract
infect
obtain
patient
streptococcu
pneumoniaeinduc
pneumonia
requir
bal
infecti
diseas
unit
n
final
recoveri
patient
present
herp
simplex
viru
type
hsv
lung
replic
relat
compensatori
antiinflammatori
respons
syndrom
car
syndrom
n
duplic
bal
perform
diagnosi
use
studi
control
virusinduc
pneumonia
bal
supernat
use
enzymelink
immunosorb
assay
elisa
bal
cell
use
rna
extract
quantit
polymeras
chain
reaction
qrtpcr
serum
sampl
serum
sampl
obtain
patient
control
sampl
obtain
serolog
biobank
institut
immunolog
gracious
provid
sylvain
dubucquoi
md
phd
sampl
renal
transplant
recipi
compar
immunosuppress
therapi
use
control
patient
patient
immunolog
analysi
perform
prior
merscov
infect
novemb
context
histamineinduc
angioedema
biobank
sampl
use
studi
control
qrtpcr
express
analysi
sampl
kept
rna
extract
perform
use
qiagen
rneasi
mini
kit
qiagen
uk
isol
rna
reversetranscrib
high
capac
cdna
revers
transcript
kit
life
technolog
uk
accord
manufactur
cytokin
assay
cytokin
level
bal
supernat
sera
assess
elisa
human
duoset
kit
r
system
uk
human
readytogo
kit
ebiosci
usa
ifna
ifnc
statist
analysi
perform
use
prism
softwar
graphpad
kruskallw
test
use
comparison
except
otherwis
indic
signific
accept
obtain
approv
lill
hospit
ethic
committe
particip
provid
written
verbal
conform
particip
studi
consent
procedur
approv
ethic
committe
patient
manuscript
next
kin
given
written
inform
consent
verbal
consent
patient
man
undergon
renal
transplant
endstag
renal
failur
secondari
diabet
treatment
associ
mycophenol
mofetil
ciclosporin
prednison
clinic
symptom
began
april
transfer
intens
care
unit
intub
april
may
patient
requir
implement
extracorpor
membran
oxygen
ecmo
die
may
refractori
multipl
organ
failur
patient
man
admit
april
medic
histori
includ
histamineinduc
angioedema
treat
system
corticosteroid
therapi
patient
share
patient
room
april
april
may
patient
present
asthenia
myalgia
cough
may
intub
transfer
intens
care
unit
lill
univers
teach
hospit
ecmo
implement
may
refractori
hypoxemia
despit
optim
treatment
patient
success
wean
ecmo
june
juli
percutan
tracheotomi
perform
current
patient
abl
breath
spontan
hour
per
day
requir
day
intermitt
haemodialysi
per
week
analys
express
main
receptor
regul
involv
recognit
doubl
strand
rna
dsrna
coronavirida
cell
isol
initi
bal
sampl
patient
day
onset
clinic
symptom
compat
merscov
infect
fever
rigor
chill
patient
show
patient
could
induc
express
key
receptor
figur
respons
merscov
infect
moreov
express
decreas
figur
lead
dramat
decreas
ifna
express
figur
without
differ
ifnb
express
figur
ifna
secret
bal
supernat
serum
consist
previou
find
ifna
level
decreas
sera
bal
patient
compar
patient
figur
none
marker
activ
control
hsv
streptococcu
pneumonia
infect
viral
stimul
pulmonari
antigen
present
cell
alveolar
macrophag
dendrit
cell
lead
secret
contribut
activ
lymphocyt
lymphocyt
recognit
cell
promot
secret
ifnc
contribut
earli
immun
respons
induc
death
infect
cell
activ
two
key
cell
involv
viral
clearanc
effector
natur
killer
nk
cell
report
ifnc
level
decreas
bal
supernat
patient
compar
patient
figur
furthermor
kinet
analysi
ifnc
level
sera
infect
show
patient
promot
earli
respons
mediat
ifnc
respons
merscov
figur
convers
patient
increas
ifnc
bal
sera
interestingli
analysi
merscov
load
serum
quantit
pcr
show
patient
rapidli
clear
viru
compart
viru
remain
detect
serum
patient
death
figur
also
measur
serum
level
epitheli
chemokin
sinc
two
cytokin
associ
poor
outcom
viral
infect
particularli
sarscov
acut
respiratori
infect
fact
poor
outcom
correl
uncontrol
durabl
secret
consist
find
found
patient
initi
promot
secret
respons
merscov
figur
howev
patient
respons
transient
first
week
follow
onset
first
symptom
patient
persist
increas
level
recent
studi
josset
et
al
demonstr
vitro
microarray
analysi
merscov
could
promot
express
compar
sarscov
consist
find
report
merscov
increas
express
lung
figur
assess
secret
bal
supernat
show
secret
increas
patient
respons
merscov
figur
higher
level
patient
compar
patient
hypothes
involv
secret
known
human
trigger
secret
respons
virus
end
assess
secret
lung
found
secret
significantli
increas
bal
patient
compar
patient
figur
final
found
elev
level
serum
patient
first
day
follow
infect
merscov
figur
interestingli
secret
increas
bal
supernat
patient
hsv
replic
mani
question
remain
answer
option
treatment
major
concern
medic
commun
although
difficult
draw
simpl
line
clinic
observ
therapeut
protocol
analysi
host
respons
cornerston
design
relev
approach
report
character
immun
respons
two
patient
differ
outcom
highlight
critic
role
ifna
innat
immun
respons
orchestr
earli
adapt
respons
mediat
ifnc
merscov
infect
previou
studi
report
critic
role
ifna
orchestr
earli
immun
respons
viral
infect
sarscov
upregul
express
mhc
class
ii
studi
show
patient
present
poor
outcom
signific
decreas
receptor
regul
involv
recognit
merscov
decreas
associ
major
decreas
ifna
express
secret
bal
well
serum
josset
et
al
demonstr
vitro
microarray
analysi
merscov
like
sarscov
suppress
antigen
present
pathway
downregul
type
ii
major
histocompat
complex
mhc
gene
assess
consequ
downregul
quantifi
product
two
key
cytokin
ifnc
involv
activ
lymphocyt
cell
result
show
clear
differ
two
patient
signific
increas
ifnc
patient
analysi
viral
clearanc
show
patient
rapidli
clear
infect
neg
blood
sampl
end
first
week
merscov
detect
serum
patient
death
although
imposs
conclud
basi
preliminari
data
suggest
ifn
respons
consist
medic
literatur
major
compon
success
antivir
host
respons
previou
studi
focus
outcom
sarscov
infect
patient
show
earli
robust
innat
immun
respons
mediat
ifn
led
high
level
ifnstimul
cytokin
requir
develop
effect
adapt
immun
respons
support
observ
patient
exhibit
persist
viral
replic
high
level
ifn
trigger
chemokin
convers
patient
surviv
could
promot
ifn
respons
control
viral
replic
downregul
respons
exhibit
low
level
recov
infect
cytokin
associ
adapt
immun
respons
repress
ifnc
secret
associ
poor
outcom
earli
stage
sarscov
infect
observ
patient
show
persist
secret
instead
antivir
immun
respons
may
contribut
poor
outcom
final
josset
et
al
previous
show
merscov
could
promot
express
vitro
confirm
observ
lung
sera
patient
lesser
extent
patient
recent
studi
report
critic
role
lymphocyt
promot
secret
inde
directli
interact
rorct
rarrel
orphan
receptor
gamma
avoid
activ
promot
differenti
lymphocyt
show
patient
express
respons
merscov
secret
low
level
ifna
high
level
lung
serum
convers
patient
express
high
level
figur
trigger
ifna
secret
lung
secret
decreas
human
exhibit
high
polymorph
may
explain
differ
immun
respons
outcom
patient
investig
may
requir
sequenc
key
protein
two
patient
may
contribut
better
understand
host
suscept
merscov
infect
base
analysi
clinic
cours
two
patient
complet
differ
outcom
emphas
major
role
host
immun
respons
merscov
infect
result
suggest
key
role
interferon
pathway
hypothesi
treatment
alpha
interferon
repres
attract
pathophysiolog
approach
diseas
sever
author
suggest
coronavirus
could
evad
host
respons
blunt
interferon
pathway
patient
abl
trigger
ifn
product
could
optim
viral
clearanc
develop
control
immun
respons
absenc
pathogen
recognit
could
lead
viral
replic
uncontrol
immun
respons
figur
administr
interferon
could
therefor
enhanc
host
respons
molecul
suggest
recent
review
publish
momattin
et
al
activ
trigger
irf
lead
product
ifna
ifn
activ
anti
viral
effector
like
cell
allow
viral
clearanc
right
panel
absenc
recognit
decreas
irf
associ
decreas
product
il
ifnc
il
product
repress
ifnc
secret
lead
decreas
lymphocyt
prolifer
increas
viral
replic
